Review Article

-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies

Table 3

Studies of quantification of α-synuclein level in blood of patients with DLB and other synucleinopathies.

MethodsSamples*Results**

El-Agnaf et al. [57]ELISAPlasma
Cont (27), PD/DLB (34)
α-Synuclein oligomers were elevated in patients with PD/DLB compared to controls.
  437025.tab.003Lee et al. [58]ELISAPlasma
Cont (51), PD (105), MSA (38)
The α-synuclein level was increased in patients with PD (79.9 pg/mL) and in those with MSA (78.1 pg/mL) compared with controls (76.1 pg/mL). The α-synuclein level was significantly higher in patients with PD than in those with MSA.
Duran et al. [59]ELISAPlasma
Cont (60), PD (95)
The α-synuclein level was elevated in patients with PD compared to healthy controls. Antiparkinsonian treatment does not change plasma α-synuclein level.
Foulds et al. [60]ELISAPlasma
(not described)
The level of phosphorylated α-synuclein was higher in patients with PD than healthy controls. None of the levels of total α-synuclein, oligomeric α-synuclein, or oligomeric phospohorylated α-synuclein was different between PD patients and controls.

437025.tab.002Shi et al. [61]Bead-based flow cytometric assayPlasma
Cont (95), AD (33), PD (117)
No significant difference was found among patients with PD (36.8 ng/mL), AD (32.4 ng/mL), and those with healthy controls (39.5 ng/mL).
Park et al. [51]ELISAPlasma
Cont (29), PD(23)
There was no difference in oligomeric and total α-synuclein in plasma between PD patients and controls.

437025.tab.001Li et al. [62]IP-Western blotPlasma
Cont (11), PD (27)
The α-synuclein level was significantly lower in patients with PD than in those with age-matched healthy controls. Early-onset PD patients had lower α-synuclein levels than late-onset PD patients.
Laske et al. [63]ELISASerum
Cont (40), AD (80), DLB (40)
The α-synuclein level was significantly lower in patients with DLB (4.7 ng/mL) than in those with AD (7.0 ng/mL) and healthy controls (8.1 ng/mL).

Arrows indicate increased (↑), comparable (→), and decreased () levels of α-synuclein.*Sample numbers are shown in parenthesis. **Values are indicated as mean or median. AD: Alzheimer’s disease; Cont: controls; DLB: dementia with Lewy bodies; IP: immunoprecipitation; MSA: multiple system atrophy; PD: Parkinson’s disease.